@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://hl7.org/fhir/uv/ebm/Composition/399873> a fhir:Composition ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "399873"] ; # 
  fhir:meta [
     fhir:versionId [ fhir:v "5" ] ;
     fhir:lastUpdated [ fhir:v "2025-12-11T20:35:21.032Z"^^xsd:dateTime ] ;
     fhir:profile ( [
       fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"^^xsd:anyURI ;
       fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report>
     ] )
  ] ; # 
  fhir:language [ fhir:v "en"] ; # 
  fhir:text [
     fhir:status [ fhir:v "generated" ] ;
     fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 399873</b></p><a name=\"399873\"> </a><a name=\"hc399873\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/399873\">https://fevir.net/resources/Composition/399873</a></p><p><b>identifier</b>: FEvIR Object Identifier/399873, FEvIR Linking Identifier/NCT03421379-outcome-measure-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Outcome Measures Report for NCT03421379</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json.</p>\n</div></td></tr></table></div>"^^rdf:XMLLiteral ]
  ] ; # 
  fhir:url [
     fhir:v "https://fevir.net/resources/Composition/399873"^^xsd:anyURI ;
     fhir:l <https://fevir.net/resources/Composition/399873>
  ] ; # 
  fhir:identifier ( [
     fhir:type [
       fhir:coding ( [
         fhir:system [
           fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ;
           fhir:l <http://terminology.hl7.org/CodeSystem/v2-0203>
         ] ;
         fhir:code [ fhir:v "ACSN" ] ;
         fhir:display [ fhir:v "Accession ID" ]
       ] ) ;
       fhir:text [ fhir:v "FEvIR Object Identifier" ]
     ] ;
     fhir:system [
       fhir:v "https://fevir.net/FOI"^^xsd:anyURI ;
       fhir:l <https://fevir.net/FOI>
     ] ;
     fhir:value [ fhir:v "399873" ] ;
     fhir:assigner [
       fhir:display [ fhir:v "Computable Publishing LLC" ]
     ]
  ] [
     fhir:type [
       fhir:text [ fhir:v "FEvIR Linking Identifier" ]
     ] ;
     fhir:system [
       fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
       fhir:l <https://fevir.net/FLI>
     ] ;
     fhir:value [ fhir:v "NCT03421379-outcome-measure-report" ] ;
     fhir:assigner [
       fhir:display [ fhir:v "Computable Publishing LLC" ]
     ]
  ] ) ; # 
  fhir:status [ fhir:v "final"] ; # 
  fhir:type [
     fhir:coding ( [
       fhir:system [
         fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
         fhir:l <https://fevir.net/resources/CodeSystem/179423>
       ] ;
       fhir:code [ fhir:v "OutcomeMeasureReport" ] ;
       fhir:display [ fhir:v "OutcomeMeasureReport" ]
     ] ) ;
     fhir:text [ fhir:v "Outcome Measure Report" ]
  ] ; # 
  fhir:date [ fhir:v "2025-12-11T20:35:21.032Z"^^xsd:dateTime] ; # 
  fhir:author ( [
     fhir:display [ fhir:v "[No author listed.]" ]
  ] ) ; # 
  fhir:title [ fhir:v "Outcome Measures Report for NCT03421379"] ; # 
  fhir:custodian [
     fhir:l <http://hl7.org/fhir/uv/ebm/Organization/118079> ;
     fhir:reference [ fhir:v "Organization/118079" ] ;
     fhir:type [
       fhir:v "Organization"^^xsd:anyURI ;
       fhir:l fhir:Organization
     ] ;
     fhir:display [ fhir:v "Computable Publishing LLC" ]
  ] ; # 
  fhir:relatesTo ( [
     fhir:type [ fhir:v "cite-as" ] ;
     fhir:target [
       a fhir:Markdown ;
       fhir:v "Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json."
     ]
  ] ) ; # 
  fhir:section ( [
     fhir:title [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration" ] ;
     fhir:focus [
       fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267226> ;
       fhir:reference [ fhir:v "EvidenceVariable/267226" ] ;
       fhir:type [
         fhir:v "EvidenceVariable"^^xsd:anyURI ;
         fhir:l fhir:EvidenceVariable
       ] ;
       fhir:identifier [
         fhir:type [
           fhir:text [ fhir:v "FEvIR Linking Identifier" ]
         ] ;
         fhir:system [
           fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
           fhir:l <https://fevir.net/FLI>
         ] ;
         fhir:value [ fhir:v "NCT03421379-primaryOutcome-0" ] ;
         fhir:assigner [
           fhir:display [ fhir:v "Computable Publishing LLC" ]
         ]
       ] ;
       fhir:display [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)" ]
     ] ;
     fhir:section ( [
       fhir:title [ fhir:v "Outcome Measure Population Description" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participant who completed both treatment visits and had evaluable treatment success data.</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Time Frame" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose up to 30 minutes post each glucagon administration</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Group List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeGroupList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Glucagon Nasal Powder" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG000" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ]
         ] )
       ] [
         fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG001" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ]
         ] )
       ] )
     ] [
       fhir:title [ fhir:v "Outcome Class List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeClassList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)" ] ;
         fhir:code [
           fhir:coding ( [
             fhir:system [
               fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
               fhir:l <https://fevir.net/resources/CodeSystem/179423>
             ] ;
             fhir:code [ fhir:v "results" ] ;
             fhir:display [ fhir:v "Results" ]
           ] )
         ] ;
         fhir:focus [
           fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267226> ;
           fhir:reference [ fhir:v "EvidenceVariable/267226" ] ;
           fhir:type [
             fhir:v "EvidenceVariable"^^xsd:anyURI ;
             fhir:l fhir:EvidenceVariable
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-primaryOutcome-0" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)" ]
         ] ;
         fhir:entry ( [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267232> ;
           fhir:reference [ fhir:v "Evidence/267232" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-primaryOutcomeMeasure-0--OG000" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267233> ;
           fhir:reference [ fhir:v "Evidence/267233" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-primaryOutcomeMeasure-0--OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267244> ;
           fhir:reference [ fhir:v "Evidence/267244" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379" ]
         ] )
       ] )
     ] )
  ] [
     fhir:title [ fhir:v "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration" ] ;
     fhir:focus [
       fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267227> ;
       fhir:reference [ fhir:v "EvidenceVariable/267227" ] ;
       fhir:type [
         fhir:v "EvidenceVariable"^^xsd:anyURI ;
         fhir:l fhir:EvidenceVariable
       ] ;
       fhir:identifier [
         fhir:type [
           fhir:text [ fhir:v "FEvIR Linking Identifier" ]
         ] ;
         fhir:system [
           fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
           fhir:l <https://fevir.net/FLI>
         ] ;
         fhir:value [ fhir:v "NCT03421379-secondaryOutcome-0" ] ;
         fhir:assigner [
           fhir:display [ fhir:v "Computable Publishing LLC" ]
         ]
       ] ;
       fhir:display [ fhir:v "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
     ] ;
     fhir:section ( [
       fhir:title [ fhir:v "Outcome Measure Population Description" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data.</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Time Frame" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Group List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeGroupList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Glucagon Nasal Powder" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG000" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ]
         ] )
       ] [
         fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG001" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ]
         ] )
       ] )
     ] [
       fhir:title [ fhir:v "Outcome Class List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeClassList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ] ;
         fhir:code [
           fhir:coding ( [
             fhir:system [
               fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
               fhir:l <https://fevir.net/resources/CodeSystem/179423>
             ] ;
             fhir:code [ fhir:v "results" ] ;
             fhir:display [ fhir:v "Results" ]
           ] )
         ] ;
         fhir:focus [
           fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267227> ;
           fhir:reference [ fhir:v "EvidenceVariable/267227" ] ;
           fhir:type [
             fhir:v "EvidenceVariable"^^xsd:anyURI ;
             fhir:l fhir:EvidenceVariable
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcome-0" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
         ] ;
         fhir:entry ( [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267234> ;
           fhir:reference [ fhir:v "Evidence/267234" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-0--OG000" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267235> ;
           fhir:reference [ fhir:v "Evidence/267235" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-0--OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379" ]
         ] )
       ] )
     ] )
  ] [
     fhir:title [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration" ] ;
     fhir:focus [
       fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267228> ;
       fhir:reference [ fhir:v "EvidenceVariable/267228" ] ;
       fhir:type [
         fhir:v "EvidenceVariable"^^xsd:anyURI ;
         fhir:l fhir:EvidenceVariable
       ] ;
       fhir:identifier [
         fhir:type [
           fhir:text [ fhir:v "FEvIR Linking Identifier" ]
         ] ;
         fhir:system [
           fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
           fhir:l <https://fevir.net/FLI>
         ] ;
         fhir:value [ fhir:v "NCT03421379-secondaryOutcome-1" ] ;
         fhir:assigner [
           fhir:display [ fhir:v "Computable Publishing LLC" ]
         ]
       ] ;
       fhir:display [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
     ] ;
     fhir:section ( [
       fhir:title [ fhir:v "Outcome Measure Population Description" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PD data.</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Time Frame" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Group List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeGroupList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Glucagon Nasal Powder" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG000" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ]
         ] )
       ] [
         fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG001" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ]
         ] )
       ] )
     ] [
       fhir:title [ fhir:v "Outcome Class List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeClassList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ] ;
         fhir:code [
           fhir:coding ( [
             fhir:system [
               fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
               fhir:l <https://fevir.net/resources/CodeSystem/179423>
             ] ;
             fhir:code [ fhir:v "results" ] ;
             fhir:display [ fhir:v "Results" ]
           ] )
         ] ;
         fhir:focus [
           fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267228> ;
           fhir:reference [ fhir:v "EvidenceVariable/267228" ] ;
           fhir:type [
             fhir:v "EvidenceVariable"^^xsd:anyURI ;
             fhir:l fhir:EvidenceVariable
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcome-1" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
         ] ;
         fhir:entry ( [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267236> ;
           fhir:reference [ fhir:v "Evidence/267236" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-1--OG000" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267237> ;
           fhir:reference [ fhir:v "Evidence/267237" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-1--OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379" ]
         ] )
       ] )
     ] )
  ] [
     fhir:title [ fhir:v "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration" ] ;
     fhir:focus [
       fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267229> ;
       fhir:reference [ fhir:v "EvidenceVariable/267229" ] ;
       fhir:type [
         fhir:v "EvidenceVariable"^^xsd:anyURI ;
         fhir:l fhir:EvidenceVariable
       ] ;
       fhir:identifier [
         fhir:type [
           fhir:text [ fhir:v "FEvIR Linking Identifier" ]
         ] ;
         fhir:system [
           fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
           fhir:l <https://fevir.net/FLI>
         ] ;
         fhir:value [ fhir:v "NCT03421379-secondaryOutcome-2" ] ;
         fhir:assigner [
           fhir:display [ fhir:v "Computable Publishing LLC" ]
         ]
       ] ;
       fhir:display [ fhir:v "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
     ] ;
     fhir:section ( [
       fhir:title [ fhir:v "Outcome Measure Population Description" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Time Frame" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Group List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeGroupList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Glucagon Nasal Powder" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG000" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ]
         ] )
       ] [
         fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG001" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ]
         ] )
       ] )
     ] [
       fhir:title [ fhir:v "Outcome Class List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeClassList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ] ;
         fhir:code [
           fhir:coding ( [
             fhir:system [
               fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
               fhir:l <https://fevir.net/resources/CodeSystem/179423>
             ] ;
             fhir:code [ fhir:v "results" ] ;
             fhir:display [ fhir:v "Results" ]
           ] )
         ] ;
         fhir:focus [
           fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267229> ;
           fhir:reference [ fhir:v "EvidenceVariable/267229" ] ;
           fhir:type [
             fhir:v "EvidenceVariable"^^xsd:anyURI ;
             fhir:l fhir:EvidenceVariable
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcome-2" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
         ] ;
         fhir:entry ( [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267238> ;
           fhir:reference [ fhir:v "Evidence/267238" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-2--OG000" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267239> ;
           fhir:reference [ fhir:v "Evidence/267239" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-2--OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379" ]
         ] )
       ] )
     ] )
  ] [
     fhir:title [ fhir:v "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration" ] ;
     fhir:focus [
       fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267230> ;
       fhir:reference [ fhir:v "EvidenceVariable/267230" ] ;
       fhir:type [
         fhir:v "EvidenceVariable"^^xsd:anyURI ;
         fhir:l fhir:EvidenceVariable
       ] ;
       fhir:identifier [
         fhir:type [
           fhir:text [ fhir:v "FEvIR Linking Identifier" ]
         ] ;
         fhir:system [
           fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
           fhir:l <https://fevir.net/FLI>
         ] ;
         fhir:value [ fhir:v "NCT03421379-secondaryOutcome-3" ] ;
         fhir:assigner [
           fhir:display [ fhir:v "Computable Publishing LLC" ]
         ]
       ] ;
       fhir:display [ fhir:v "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
     ] ;
     fhir:section ( [
       fhir:title [ fhir:v "Outcome Measure Population Description" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Time Frame" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Group List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeGroupList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Glucagon Nasal Powder" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG000" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ]
         ] )
       ] [
         fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG001" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ]
         ] )
       ] )
     ] [
       fhir:title [ fhir:v "Outcome Class List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeClassList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ] ;
         fhir:code [
           fhir:coding ( [
             fhir:system [
               fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
               fhir:l <https://fevir.net/resources/CodeSystem/179423>
             ] ;
             fhir:code [ fhir:v "results" ] ;
             fhir:display [ fhir:v "Results" ]
           ] )
         ] ;
         fhir:focus [
           fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267230> ;
           fhir:reference [ fhir:v "EvidenceVariable/267230" ] ;
           fhir:type [
             fhir:v "EvidenceVariable"^^xsd:anyURI ;
             fhir:l fhir:EvidenceVariable
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcome-3" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
         ] ;
         fhir:entry ( [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267240> ;
           fhir:reference [ fhir:v "Evidence/267240" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-3--OG000" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267241> ;
           fhir:reference [ fhir:v "Evidence/267241" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-3--OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379" ]
         ] )
       ] )
     ] )
  ] [
     fhir:title [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration" ] ;
     fhir:focus [
       fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267231> ;
       fhir:reference [ fhir:v "EvidenceVariable/267231" ] ;
       fhir:type [
         fhir:v "EvidenceVariable"^^xsd:anyURI ;
         fhir:l fhir:EvidenceVariable
       ] ;
       fhir:identifier [
         fhir:type [
           fhir:text [ fhir:v "FEvIR Linking Identifier" ]
         ] ;
         fhir:system [
           fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
           fhir:l <https://fevir.net/FLI>
         ] ;
         fhir:value [ fhir:v "NCT03421379-secondaryOutcome-4" ] ;
         fhir:assigner [
           fhir:display [ fhir:v "Computable Publishing LLC" ]
         ]
       ] ;
       fhir:display [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
     ] ;
     fhir:section ( [
       fhir:title [ fhir:v "Outcome Measure Population Description" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Measure Time Frame" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ]
       ] ;
       fhir:text [
         fhir:status [ fhir:v "generated" ] ;
         fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"^^rdf:XMLLiteral ]
       ]
     ] [
       fhir:title [ fhir:v "Outcome Group List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeGroupList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "Glucagon Nasal Powder" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG000" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ]
         ] )
       ] [
         fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ;
         fhir:code [
           fhir:text [ fhir:v "OG001" ]
         ] ;
         fhir:text [
           fhir:status [ fhir:v "generated" ] ;
           fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ]
         ] ;
         fhir:entry ( [
           fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ]
         ] )
       ] )
     ] [
       fhir:title [ fhir:v "Outcome Class List" ] ;
       fhir:code [
         fhir:text [ fhir:v "OutcomeClassList" ]
       ] ;
       fhir:section ( [
         fhir:title [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ] ;
         fhir:code [
           fhir:coding ( [
             fhir:system [
               fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
               fhir:l <https://fevir.net/resources/CodeSystem/179423>
             ] ;
             fhir:code [ fhir:v "results" ] ;
             fhir:display [ fhir:v "Results" ]
           ] )
         ] ;
         fhir:focus [
           fhir:l <http://hl7.org/fhir/uv/ebm/EvidenceVariable/267231> ;
           fhir:reference [ fhir:v "EvidenceVariable/267231" ] ;
           fhir:type [
             fhir:v "EvidenceVariable"^^xsd:anyURI ;
             fhir:l fhir:EvidenceVariable
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcome-4" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)" ]
         ] ;
         fhir:entry ( [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267242> ;
           fhir:reference [ fhir:v "Evidence/267242" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-4--OG000" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379" ]
         ] [
           fhir:l <http://hl7.org/fhir/uv/ebm/Evidence/267243> ;
           fhir:reference [ fhir:v "Evidence/267243" ] ;
           fhir:type [
             fhir:v "Evidence"^^xsd:anyURI ;
             fhir:l fhir:Evidence
           ] ;
           fhir:identifier [
             fhir:type [
               fhir:text [ fhir:v "FEvIR Linking Identifier" ]
             ] ;
             fhir:system [
               fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
               fhir:l <https://fevir.net/FLI>
             ] ;
             fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-4--OG001" ] ;
             fhir:assigner [
               fhir:display [ fhir:v "Computable Publishing LLC" ]
             ]
           ] ;
           fhir:display [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379" ]
         ] )
       ] )
     ] )
  ] ) . # 

<http://hl7.org/fhir/uv/ebm/Organization/118079> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/EvidenceVariable/267226> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267232> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267233> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267244> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/EvidenceVariable/267227> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267234> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267235> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/EvidenceVariable/267228> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267236> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267237> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/EvidenceVariable/267229> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267238> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267239> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/EvidenceVariable/267230> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267240> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267241> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/EvidenceVariable/267231> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267242> a fhir:Uv .

<http://hl7.org/fhir/uv/ebm/Evidence/267243> a fhir:Uv .

# -------------------------------------------------------------------------------------